Cogent Biosciences (NASDAQ: COGT) net income
Cogent Biosciences reported a net loss of $328.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $255.9m. Earnings per share were −$2.16.
Cogent Biosciences's best year of the last 9 was fiscal 2017. It reported a loss in 9 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$328.9m | — | — | −$2.16 |
| 2024 | −$255.9m | — | — | −$1.94 |
| 2023 | −$192.4m | — | — | −$2.42 |
| 2022 | −$140.2m | — | — | −$2.39 |
| 2021 | −$72.3m | — | — | −$1.87 |
| 2020 | −$74.8m | — | −950.4% | — |
| 2019 | −$31.8m | — | −141.5% | — |
| 2018 | −$34.5m | — | −354.8% | — |
| 2017 | −$25.5m | — | −304.9% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Cogent Biosciences net income compared with its sector
By net income for its latest fiscal year, Cogent Biosciences ranks 453rd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 451st | Ginkgo Bioworks | −$312.8m | −183.8% |
| 452nd | Replimune Group | −$313.9m | — |
| 453rd | Cogent Biosciences | −$328.9m | — |
| 454th | Viridian Therapeutics | −$342.6m | −483.6% |
| 455th | Xenon Pharmaceuticals | −$345.9m | −4,612.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Cogent Biosciences
- How much did Cogent Biosciences earn in fiscal 2025?
- Cogent Biosciences reported a net loss of $328.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $255.9m.
- What are the earnings per share of Cogent Biosciences?
- They were −$2.16 in fiscal 2025, compared with −$1.94 in fiscal 2024.
- Where does Cogent Biosciences rank in its sector by net income?
- It ranks 453rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Cogent Biosciences come from?
- From the annual report (Form 10-K) that Cogent Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Cogent Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Cogent Biosciences: the Cogent Biosciences page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.